– USA, CA – EBR Systems, Inc., developer of the world’s only wireless cardiac pacing system for heart failure, today announced the appointment of Dr. Bronwyn Evans, Dr. David Steinhaus, and Karen Drexler to its Board as Independent Non-Executive Directors.
“I am very excited to welcome Dr Evans, Dr Steinhaus and Ms Drexler to our Board of Directors, who together bring a wealth of clinical and commercial experience across the healthcare industry, which will be of significant value to EBR Systems.” said Board Chair, Allan Will.
These appointments follow the retirement of Dave Stassen and Dr. Leighton Read from the Board.
About Dr. Bronwyn Evans
Dr. Evans is an experienced leader and CEO with a broad technical background across multiple industry sectors. She is currently the CEO of Engineers Australia, the Chair of Building 4.0 CRC, and a Director at GME Pty Ltd. She has an extensive background in the healthcare industry having previously served as the CEO of Standards Australia, SVP of Quality, Clinical & Regulatory at Cochlear Limited (ASX: COH), and held multiple other executive roles. She was named as one of Australia’s Top 100 Influential Women in 2016.
Dr. Evans holds a bachelor’s degree and a Ph.D. in Electrical Engineering from the University of Wollongong.
About Dr. David Steinhaus
Dr. Steinhaus was formerly VP and GM of the Heart Failure Business for the Cardiac Rhythm and Heart Failure Division at Medtronic Plc (NYSE: MDT). Dr. Steinhaus has extensive clinical and business experience in cardiac rhythm management, including performing numerous clinical studies in implantable cardiac devices and leads. He is currently the Executive Chairman of the board at Enopace Biomedical Ltd., a company which produces therapeutic neuromodulation devices for the treatment of heart failure, and serves as a consultant and board member for multiple established and early-stage medical device companies.
Dr. Steinhaus is a magna cum laude graduate of Harvard College and received his medical doctorate from Harvard Medical School as part of the Harvard-M.I.T. program in Health Sciences and Technology, with Alpha Omega Alpha honors.
About Karen Drexler
Ms. Drexler brings an array of operational and entrepreneurial experience to EBR System’s Board. She is currently a Director at Resmed Inc. (NYSE, ASX: RMD), where she serves on the compensation committee and the nominating and governance committee, and a Director at Outset Medical Inc. (NASDAQ: OM), where she chairs the compensation committee and serves on the nomination and governance committee. Ms. Drexler also serves on the board of three private companies: Bone Health Technologies Inc., VIDA Diagnostics Inc., and Tivic Health Systems Inc., which are all in the medical technology sector.
Karen graduated with a bachelor’s degree in chemical engineering from Princeton University and earned an MBA with honors from the Stanford University Graduate School of Business.
About EBR Systems
Silicon Valley-based EBR Systems is dedicated to the superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring CRT. Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.
EBR Systems is backed by respected private equity investors including M.H. Carnegie & Co., Brandon Capital Partners, Split Rock Partners, Ascension Ventures, and Emergent Medical Partners.
For more information: https://ebrsystemsinc.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
